Drug candidate
|
Frequency
|
Percent of responses
|
Percent of cases
|
Meplazumab
|
1
|
0.44
|
0.81
|
Leflumide
|
1
|
0.44
|
0.81
|
Camrelizumab
|
1
|
0.44
|
0.81
|
Ulinastatin
|
1
|
0.44
|
0.81
|
Bevacizumab
|
2
|
0.88
|
1.61
|
Thalidomide
|
2
|
0.88
|
1.61
|
Suramin
|
1
|
0.44
|
0.81
|
Enoxaparin
|
1
|
0.44
|
0.81
|
Vitamin C
|
1
|
0.44
|
0.81
|
Tetrandine
|
1
|
0.44
|
0.81
|
Sildenafil
|
1
|
0.44
|
0.81
|
Heparin
|
1
|
0.44
|
0.81
|
Losartan
|
1
|
0.44
|
0.81
|